Evidence map›Paper›PMID 23547759›Full record

ArticleACS chemical biology2013

Synthesis and SAR of Lehualide B: a marine-derived natural product with potent anti-multiple myeloma activity.

Valer Jeso, Chunying Yang, Michael D Cameron, John L Cleveland, Glenn C Micalizio

Abstract read
In one paragraph

Article in ACS chemical biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. TheGenes · 2018
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Valer JesoDepartments of Chemistry, ‡Cancer Biology, and #Molecular Therapeutics, The Scripps Research Institute , Scripps Florida, Jupiter, Florida 33458, United States.
Chunying Yang
Michael D Cameron
John L Cleveland
Glenn C Micalizio

Funding

Stereoselective Synthesis via Metallacycle-Mediated Bond ConstructionR01GM080266 · NIGMS · YALE UNIVERSITY · PI MICALIZIO, GLENN C · 2007 to 2019
$4.8M
The Bcl-2/Bcl-X Pathway in Myc-Induced LymphomagenesisR01CA076379 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CLEVELAND, JOHN L. · 1998 to 2012
$3.5M
NCI NIH HHS CA076379NCI NIH HHS R01 CA076379NIGMS NIH HHS GM80266NIGMS NIH HHS GM80266-04S1NIGMS NIH HHS R01 GM080266
6 · The paper itself

Abstract

We report a concise and convergent laboratory synthesis of the rare marine natural product lehualide B that has led to the discovery that (1) this compound has low nanomolar activity against human multiple myeloma cells and (2) the anticancer effects of lehualide B and its analogues are selective (i.e., they are approximately 2-3 orders of magnitude less toxic to human breast cancer cells). Synthetic lehualide B is shown to be an effective inhibitor of complex I of the mitochondrial electron transport chain, with potency similar to that observed for the terrestrial natural products piericidin A1 and rotenone, an observation that led to the discovery that piericidin A1 is also selectively cytotoxic toward human multiple myeloma cells. Interestingly, synthetic derivatives of lehualide B that resemble verticipyrone (an established complex I inhibitor composed of a γ-pyrone and a simple monounsaturated hydrophobic chain) lack the potent antimyeloma activity of the natural product. Finally, the synthesis and evaluation of a collection of lehualide-inspired analogues led to the elucidation of structure-activity relationships for this rare natural product that established important roles for the substituted γ-pyrone headgroup and the skipped polyene side chain.

Indexed as

Antineoplastic AgentsBiological ProductsCell Line, TumorHumansMultiple MyelomaPyronesAntineoplastic AgentsBiological Productslehualide BPyrones

Identifiers

PMID23547759
PMCPMC3758376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.